GENE ONLINE|News &
Opinion
Blog

2020-10-13| Asia-Pacific

ITRI and Gemseki Agreed on the Collaboration of Licensing Activities

by GeneOnline
Share To

Industrial Technology Research Institute (ITRI), the applied technology institution in Taiwan, has agreed with Gemseki Inc. (Gemseki) for the collaboration on licensing and partnering of ITRI’s drug candidates and technologies (“assets”). Under the agreement, Gemseki is conducting licensing and business development activities worldwide for ITRI’s assets. Gemseki supports to find strategic partners and helps negotiations for these assets.

Dr. Chii-Wann Lin, ITRI Vice President and General Director of Biomedical Technology and Device Research Laboratories, comments, “ITRI has a lot of good drug candidates and technologies, and we are looking for partners for these assets. Gemseki has built an innovative business model and shares our vision to make innovation happen in the life science industry. Its established global network is also appealing for us, aligning with our strategy of leveraging worldwide resources. With this collaboration, I believe ITRI can expedite the commercialization of our technologies and making contributions to the world.”

Mr. Hideyuki Hirama, President and CEO of Gemseki, comments, “It is a great honor to work with ITRI, a prestigious research institution in Taiwan. I am very impressed with ITRI’s R&D capability. Also, I am very fascinated by the leadership that Dr. Lin takes to bring more innovation. We will be seeking partnering opportunities for ITRI’s great assets by utilizing our global network. We are very excited to be able to contribute to the development of the life science industry in Taiwan.”

References

  1. https://www.gemseki.com/en/news/590

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Inside the Exosome Boom: Global Experts Talk Industry Trends, Roadblocks, and What’s Next
2025-04-16
Tiny Packages, Big Promise: The Rise of Exosomes in Modern Medicine
2025-04-16
Shared Expertise, Shared Vision: Biotech Powerhouses Drive Innovation in This Billion-Dollar Market
2024-11-27
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top